Sylwia Serafińska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylwia Serafińska has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Krzysztof Simon
1st Department of Infectious Diseases, J. Gromkowski Specialist Regional Hospital, 51-149 Wroclaw, Poland
2 shared publications - Agnieszka Gomułkiewicz
Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland
1 shared publication - Anna Nowicka
First Department of Infectious Diseases, J. Gromkowski Regional Specialist Hospital, Wroclaw, Poland
1 shared publication - Jolanta Zuwała-Jagiełło
Department of Pharmaceutical Biochemistry, Wroclaw Medical University, Poland
1 shared publication - Monika Pazgan-Simon
Department of Infectious Diseases and Hepatology, Wrocław Medical University, 50-370 Wrocław, Poland
1 shared publication - Piotr Dziegiel
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1)
Metallothioneins in the Pathogenesis of Liver Diseases: A Review
Metallothioneins (MTs) are primarily known for maintaining cellular metal homeostasis and protecting against metal toxicity, but they also play critical roles in mitigating oxidative stress and modulating immune responses. Reduced MTs expression is associated with disease progression in several chronic hepatic disorders. In metabolic dysfunction–associated steatotic liver disease (MASLD), MT1 downregulation has been linked to the transition from simple steatosis to steatohepatitis. Additionally, evidence suggests that individuals with low MTs expression may be more susceptible to obesity, which is one of the key drivers in the development of MASLD. In chronic viral hepatitis, in vivo MTs downregulation contrasts with acute‐phase in vitro upregulation, suggesting an effect of persistent inflammation. MTs downregulation in hepatocellular carcinoma (HCC) correlates with poor prognosis, positioning MTs as potential biomarkers and therapeutic targets. In contrast, increased MTs expression may play a protective or diagnostically informative role in other conditions. In alcoholic hepatitis, MT1 overexpression contributes to defense against oxidative stress and inflammation. In Wilson’s disease, MTs demonstrates prominent hepatic expression and may offer diagnostic value alongside traditional markers such as rhodanine staining. In cholestatic liver diseases like PBC and PSC, MTs expression correlates with disease progression. This review highlights the emerging role of MTs in liver disease pathogenesis and positions them as promising molecular tools that may inform future strategies for diagnosis, prognosis, and treatment of liver diseases.
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1)
Open AccessMetallothioneins in the Pathogenesis of Liver Diseases: A Review
Metallothioneins (MTs) are primarily known for maintaining cellular metal homeostasis and protecting against metal toxicity, but they also play critical roles in mitigating oxidative stress and modulating immune responses. Reduced MTs expression is associated with disease progression in several chronic hepatic disorders. In metabolic dysfunction–associated steatotic liver disease (MASLD), MT1 downregulation has been linked to the transition from simple steatosis to steatohepatitis. Additionally, evidence suggests that individuals with low MTs expression may be more susceptible to obesity, which is one of the key drivers in the development of MASLD. In chronic viral hepatitis, in vivo MTs downregulation contrasts with acute‐phase in vitro upregulation, suggesting an effect of persistent inflammation. MTs downregulation in hepatocellular carcinoma (HCC) correlates with poor prognosis, positioning MTs as potential biomarkers and therapeutic targets. In contrast, increased MTs expression may play a protective or diagnostically informative role in other conditions. In alcoholic hepatitis, MT1 overexpression contributes to defense against oxidative stress and inflammation. In Wilson’s disease, MTs demonstrates prominent hepatic expression and may offer diagnostic value alongside traditional markers such as rhodanine staining. In cholestatic liver diseases like PBC and PSC, MTs expression correlates with disease progression. This review highlights the emerging role of MTs in liver disease pathogenesis and positions them as promising molecular tools that may inform future strategies for diagnosis, prognosis, and treatment of liver diseases.
- Open Access
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (4) , 121-126
Nutrition principles and recommendations in different types of hepatic encephalopathy
Appropriate nutrition – in terms of both quantity and quality – is not only one of the main life processes. A well-balanced diet including sufficient amounts of minerals and vitamins supports proper human development and functioning from fetal development to very advanced old age; it promotes...
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (4) , 121-126
Open AccessNutrition principles and recommendations in different types of hepatic encephalopathy
Appropriate nutrition – in terms of both quantity and quality – is not only one of the main life processes. A well-balanced diet including sufficient amounts of minerals and vitamins supports proper human development and functioning from fetal development to very advanced old age; it promotes...